Skip to main content
Fig. 2 | The Journal of Headache and Pain

Fig. 2

From: Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)

Fig. 2

Total pain burden sensitivity analysis: total monthly severity-weighted duration in hours adjusted for change in migraine headache days for patients with episodic migraine and chronic migraine. Greater decreases in total pain burden (severity-weighted hours) were observed with galcanezumab treatment Months 1 to 6 overall for patients with episodic migraine and Months 1 to 3 overall for patients with chronic migraine

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us